A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Once Daily Ciclesonide HFA Nasal Aerosol (80 and 160 mcg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older.
Latest Information Update: 11 Aug 2023
Price :
$35 *
At a glance
- Drugs Ciclesonide (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2013 Results from a post-hoc analysis, which included data from this trial, have been presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology according to a Sunovion Pharmaceuticals media release.
- 08 Jun 2012 Actual patient number changed from 825 to 824 as reported by ClinicalTrials.gov. (Extension trial: NCT01067105)
- 08 Jun 2012 Actual patient number changed from 825 to 824 as reported by ClinicalTrials.gov. (Extension trial: NCT01067105)